5% for Nano: A Manifesto to Revitalize the Micro-Cap Ecosystem
Nano-caps are being left behind. “5% for Nano” is a bold plan to revive innovation, create jobs, and unlock the next wave of market leaders.
ML
Marcus Laun
May 2, 2025
Latest Articles
Read the latest insights and analysis on small-cap investing, CEO interviews, and market trends.
From Legacy to Lift-Off: Flyte's Blueprint for Aviation's Next Era
Flyte is redefining the chartered jet industry by integrating the disparate infrastructure into a streamlined platform
MS
Marc Sellouk
May 1, 2025
The US Consumer as Global Superstar: Trump’s Tariff Policy Leverage
US tariff strategy is predicated on the exceptional positioning of the US economy, bolstered by its insatiable consumption habits
JMS
Joseph M Salvani
April 9, 2025
Why the US Can Impose Tariffs and Still Remain Attractive to Trading Partners
The US is unique in its ability to maintain high tariffs with trading partners thanks to its immense consumer base
JMS
Joseph M Salvani
April 4, 2025
The Great Reversal: Why a Massive Bull Market May Be Just Getting Started
After early turbulence this year, markets may be poised for a breakout
JMS
Joseph M Salvani
March 24, 2025
The $5 Million Gold Card Visa Program: A $50 Trillion Market Opportunity
Could a $5M immigration visa wipe out U.S. debt? A bold plan to attract 10M investors, raise $50T, and reshape the global economy
JMS
Joseph M Salvani
March 7, 2025
Is 2025 the Next 1926? A Historic Bull Market Forecast
History is repeating itself—1926-style. A short-lived shakeout in early 2025 could set the stage for one of the greatest bull markets in a century
JMS
Joseph M Salvani
February 27, 2025
A Hidden Threat: Naked Short Selling and Its Impact on the US Economy
Naked short selling is hurting retail investors and stifling job creation. Discover how this hidden practice manipulates the market and what reforms are needed to level the playing field and support small businesses in the U.S. economy.
JMS
Joseph M Salvani
February 19, 2025
Enzolytics (OTC: ENZC) and Creatd (OTC: CRTD): Exploring Biotech Innovation Through Strategic Transformation
A groundbreaking biotech firm's lifesaving research was nearly derailed by corporate turmoil until Creatd stepped in, transforming Enzolytics from a troubled company into a potential powerhouse in the fight against HIV, cancer, and immune disorders through innovative antibody therapies and AI-driven drug discovery.
C
CEOBLOC
February 3, 2025